Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Amazon
AMZN
5
Sirius XM
SIRI
HK Stock MarketDetailed Quotes
06160 BEIGENE
- 149.000
- +2.300+1.57%
Market Closed Apr 29 16:08 CST
208.75BMarket Cap-41.71P/E (TTM)
152.200High147.400Low3.21MVolume147.400Open146.700Pre Close480.60MTurnover0.25%Turnover RatioLossP/E (Static)1.40BShares178.00052wk High8.07P/B191.61BFloat Cap85.00052wk Low--Dividend TTM1.29BShs Float278.600Historical High--Dividend LFY3.27%Amplitude61.050Historical Low149.634Avg Price100Lot Size--Div YieldTTM--Div Yield LFY
About BEIGENE Company
The company is a limited company incorporated in the Cayman Islands and was incorporated on October 28, 2010. The Company was listed and traded on the US NASDAQ Stock Exchange (“NASDAQ”), Hong Kong Stock Exchange and Shanghai Stock Exchange on February 8, 2016, August 8, 2018, and December 15, 2021, respectively. The company focuses on R&D, production and commercialization of innovative drugs. The main products are anti-tumor drugs, etc.
Company Profile
Symbol06160
Company NameBEIGENE
ISINKYG1146Y1017
Listing DateAug 8, 2018
Issue Price108.00
Shares Offered65.60M share(s)
FoundedJun 28, 2018
Registered AddressCayman Islands
Chairmanleiqiang ou
Secretaryqingling zhou
Audit InstitutionErnst & Young, Ernst & Young LLP, Ernst & Young AG, Ernst & Young AG
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeMourant Governance Services (Cayman) Limited, 94Solaris Avenue, Camana Bay, PO Box 1348, GrandCayman KY1-1108, Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase 1, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees11000
MarketHong Kong motherboard
Phone010-58958058
Fax010-85148699
Emailir@beigene.com
Websitehttp://www.beigene.cn
BusinessBeiGene is a global, commercial-stage biotechnology company focused on the research, development, production and commercialization of innovative medicines.
Company Executives
- Name
- Position
- Salary
- leiqiang ou
- Presidencies, CEOs, Executive Director, Authorized Representative
- --
- xiaodong wang
- Non-executive Directors
- --
- Olivier Brandicourt
- Independent Non-Executive Director, Audit Committee Members
- --
- Margaret Han Dugan
- Independent Non-Executive Director, Remuneration Committee Chairman, Member of the Advisory Committee on Commercial and Medical Affairs
- --
- Michael Goller
- Independent Non-Executive Director, Nomination and Corporate Governance Committee Members
- --
- Anthony C. Hooper
- Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members
- --
- Ranjeev Krishana
- Independent Non-Executive Director, Remuneration Committee Members
- --
- Shalini Sharp
- Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
- --
- Alessandro Riva
- Independent Non-Executive Director, Nomination Committee Members
- --
- Corazon (Corsee) D. Sanders
- Independent Non-Executive Director, Audit Committee Members
- --
- qingqing yi
- Independent Non-Executive Director, Remuneration Committee Members
- --
- xiaobin wu
- President, General Manager, Chief Operating Officer
- --
- Aaron Rosenberg
- Chief Financial Officer
- --
- lai wang
- Global Head of R&D
- --
- Chan Lee
- Senior Vice President, General Counsel
- --
- qingling zhou
- Authorized Representative, Company Secretary
- --
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts